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Vascular prosthetic graft infection (VPGI) is a severe complication after vascular surgery. CT-scan is considered the diagnostic
tool of choice in advanced VPGI. The incidence of a false-negative result using CT is relatively high, especially in the presence of
low-grade infections. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scanning has been suggested as an
alternative for the diagnosis and assessment of infectious processes. Hybrid 18F-FDG PET/CT has established the role of 18F-FDG
PET for the assessment of suspected VPGI, providing accurate anatomic localization of the site of infection. However, there are no
clear guidelines for the interpretation of the uptake patterns of 18F-FDG as clinical tool for VPGI. Based on the available literature it
is suggested that a linear, diffuse, and homogeneous uptake should not be regarded as an infection whereas focal or heterogeneous
uptake with a projection over the vessel on CT is highly suggestive of infection. Nevertheless, 18F-FDG PET and 18F-FDG PET/CT
can play an important role in the detection of VPGI andmonitoring response to treatment. However an accurate uptake and pattern
recognition is warranted and cut-off uptake values and patterns need to be standardized before considering the technique to be the
new standard.
1. Introduction
Vascular prosthetic graft infection (VPGI) is an uncommon
complication after reconstructive vascular surgery with an
incidence ranging between 1 and 6%. The incidence of VPGI
varies according to the bypass localization with less than 1%
in case of subrenal aortic bypass, 1-2% after aortofemoral
bypass, and up to 6% in case of infrainguinal bypass [1–3].
Nevertheless, it is one of the most difficult challenges faced
by the vascular surgeon and is associated with devastating
complication such as limb amputation (5–25%) andmortality
rates as high as 25–88% [1–3].The first and principal dilemma
in clinically suspected VPGI is to obtain definite proof of
the graft infection. Positive cultures either frompercutaneous
aspirated perigraft fluid or from surgically obtained material
are considered by many the gold standard for VPGI but in
clinical practice are often difficult to obtain. For adequate
treatment, it is important to diagnose graft infection at an
early stage. Unfortunately, clinical signs are variable and often
subtle. They may include recurrent fevers and chills, back
or groin pain, erythema, swelling, or a pulsatile mass in the
groin, thus making the correct diagnosis sometimes tedious
[4]. The commonly used first methods to evaluate and
diagnose a VPGI are evaluation of elevated infection parame-
ters in peripheral blood samples (erythrocyte sedimentation
rate, white blood cell count, and C-reactive protein (CRP)),
duplex ultrasound scanning, computed tomography (CT)
scanning, and magnetic resonance imaging (MRI). However,
the predictive value for diagnosing VPGI with either one of
these diagnostic tools has proven to be relatively low [5]. To
date CT is considered the gold standard in diagnosing VPGI
because of its high spatial resolution providing a detailed view
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Table 1: Summary of literature data regarding the use of 18F-FDG PET imaging requested in suspected vascular graft infection.
Study Year Study Design Number ofpatient’s Imaging modality Interpretation criteria TP
1 TN2 FP3 FN4 Sens∗ % Spec∗∗ %
Fukuchi et al. [10] 2005 prospective 33 PET Semiquantitativea 10 14 8 1 91 64
Keidar et al. [13] 2007 prospective 39 PET/CT Visual 14 22 2 1 93 91
Lauwers et al. [14] 2008 case series 4 PET Visual 3 0 1 0 — —
Spacek et al. [15] 2009 prospective 76 PET/CT Semiquantitativeb 54 31 10 1 78.2 92.7
Bruggink et al. [16] 2010 retrospective 25 PET and PET/CT Semiquantitativec 15 10 0 0 93† 70†







aFive-point scale intensity of FDG uptake.
bThree point scale intensity of FDG uptake.
cFour point scale intensity of FDG uptake.
dSUVmax cut off value.
†Results for both FDG-PET and fused FDG-PET-CT, judged by a nuclear medicine physician.
of the vascular structures and perivascular spaces. Diagnostic
signs for VPGI on CT include the presence of local fluid,
perigraft retention, pseudoaneurysm formation, and focal
bowel thickening and air bubbles [6], though these findings
are present in just 50% of VPGI cases and are even considered
normal findings in the early postoperative period. Other
CT findings suggesting a VPGI include thickening of the
graft wall, adjacent blurred fat, and soft tissue swelling. CT
scan sensitivity and specificity are claimed to be 95% but
this high percentage can only be reached in clinically high
suspected VPGI [7–9]. CT scan is much less reliable in case
of a low-grade infection, with a sensitivity and specificity
of 55% and 100%, respectively [10–12]. In particular, the
false-positive results may lead to unnecessary surgery or
lengthy antibiotic use while the false-negative results may
have life or limb threatening consequences. Since 1996,
several studies have evaluated the usefulness of 18-F-Fluoro-
D-deoxyglucose positron emission tomography (18F-FDG
PET) in the detection of infectious foci and,more specific, the
usefulness in the analyses of suspected VPGI (Table 1). This
review aims to summarize the accuracy and interpretation of
18F-FDG PET in the detection of VPGI.
2. Search
A literature search was carried out using the following
databases: Pubmed, the Cochrane library, ScienceDirect, and
Embase. Two authors (Ben R. Saleem and Robert A. Pol),
independently of each other, identified the studies for inclu-
sion based on title or abstract using the following medical
subject headings (MeSH): “positron emission tomography,”
“blood vessel prosthesis,” and “infection.”These MeSH terms
were applied in various combinations using the Booleans
operators AND or OR. Papers were included from the start
of the databases until January 2014. Reference lists from
the selected articles were manually checked for additional
relevant studies. In Pubmed, the “related article” algorithm
was employed to identify additional articles. Case reports and
short case series (number of patients< 4) were excluded from
further review. In total, six original studies were selected and
listed in Table 1.
3. 18F-FDG PET Imaging in Infectious Diseases
18F-FDG PET imaging is based on uptake of radioactive-
labeled glucose (18F-FDG) in metabolically active cells. Acti-
vated inflammatory cells, like malignant cells, predominantly
metabolize glucose as a source of energy. In the stim-
ulated state, inflammatory cells, such as neutrophils and
macrophages, express high concentrations of glucose trans-
porters that facilitate the movement of FDG through the cell
membrane. The initial application was designed to diagnose
cancer as increased glucose metabolism is often present
in tumor cells, resulting in a higher 18F-FDG uptake than
in the surrounding tissues [18]. However, it appeared that
inflammatory and infectious lesions sometimes caused false-
positive results. In the early years of clinical 18F-FDG PET
imaging in oncology, cases of false-positive uptake in a wide
variety of infections were described [19]. Although initially
interpreted as false-positive results and even a disadvantage
of the technique, its usefulness in detecting inflammationwas
further exploredwith respect to the potential of 18F-FDGPET
imaging in different types of infection and inflammation [20,
21] (Figure 1). To increase the sensitivity and specificity FDG-
PET can be fusedwithCTandorMR images.Hybrid PET/CT
has been increasingly applied during the last decade [22]. 18F-
FDG PET/CT can identify infections and their relation to the
surrounding anatomy. Hybrid PET/MR has rapidly increased
in interest in daily clinical practice. PET/MR also provides
the anatomic information but with much higher soft tissue
contrast and without the additional radiation dose from CT
[23, 24]. Todate themajority of reports on the role of 18F-FDG
PET and fused 18F-FDG PET/CT imaging in the diagnosis
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Figure 1: Coronal and axial view of fused 18F-FDG PET/CT images. In this particular case, a 67-year-old male patient underwent an aorto-
bi-iliac bypass 16 years ago. After 3 years the bypass was revised because of an occlusion. Five years later the second bypass also occluded and
an axillobifemoral bypass was constructed. Unfortunately this bypass also occluded twice. Patient is admitted to the hospital because of pain
and redness at the level of the axillobifemoral bypass probably due to infection. 18F-FDG PET/CT scanning showed increased FDG uptake
at the level of both occluded bypasses, the aorto-bi-iliac bypass and the axillobifemoral bypass. Arrows are pointing at increased FDG uptake
in both bypasses. Ultimately, no bacteria were cultured.
of VPGI are case series and case reports of single patients
[10, 13–17, 25, 26].
4. Accuracy of 18F-FDG PET in VPGI
The sensitivity and specificity of 18F-FDG PET vary greatly in
current literature. Table 1 summarizes data on the use of 18F-
FDG PET and fused 18F-FDG PET/CT imaging in suspected
VPGI. In a large case series of 33 patients that compared
the feasibility of 18F-FDG PET with CT, the sensitivity and
specificity of 18F-FDG PET were, respectively, 91 and 64%
[10]. Comparably, if no better results were published by
Keidar et al. they prospectively assessed 39 patients (69
vascular prosthetic grafts) with suspected VPGI by 18F-FDG
PET fused with CT. 18F-FDG PET/CT results were true
positive in 14, false negative in 1, and false positive in 2
cases, resulting in sensitivity and specificity rates of 93% and
91%, respectively [13]. Spacek et al. also evaluated fused 18F-
FDG PET/CT images in 76 patients (96 vascular prosthetic
grafts) with suspected VPGI [15]. Although in this paper the
specificity was similarly high with 93%, the sensitivity of 78%
was remarkably low. The most recent study by our group
evaluated both 18F-FDG PET and fused 18F-FDG PET/CT
imaging. In a retrospective study a sensitivity of 93% and
a specificity of 70% of 18F-FDG PET in 25 patients with
clinically suspected VPGI were found [16]. We found no
differences regarding sensitivity or specificitywhen fused 18F-
FDG PET/CT images were assessed for their accuracy in
diagnosing VPGI. Also no differences have been found in
the literature yet on accuracy of 18F-FDG PET/CT between
abdominal versus thoracic aorta graft infection [17].
5. Interpretation and Grading of
the 18F-FDG PET Findings
There is no consensus with respect to the interpretation
of the 18F-PET findings in the reviewed studies wherein a
visual grading scale was used. Different variants such as a
four- or five-point scale were used [10, 16]. The five-point
scale was structured as follows: grade 0, FDG uptake similar
to that in the background, grade 1, with low FDG uptake,
comparable with that by inactive muscles and fat, grade
2, with moderate FDG uptake, clearly visible and higher
than the uptake by inactive muscles and fat, grade 3, with
strong FDG uptake, but distinctly less than the physiologic
uptake by the bladder, and grade 4, with very strong FDG
uptake, comparable with the physiologic urinary uptake by
the bladder. Using this classification, lesions with grades 3
and 4 uptake are considered infected lesions [20]. The four-
point grading scale consists of grade 1, with FDG uptake
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similar to that in the background, grade 2, with low FDG
uptake, comparable with that by inactive muscles and fat,
grade 3, withmoderate FDGuptake, clearly visible and higher
than the uptake by inactive muscles and fat, but distinctly
less than the physiologic uptake by the bladder, and grade
4, with strong FDG uptake, comparable with the physiologic
urinary uptake by the bladder. Lesions with grades 3 and 4
uptake were classified as high probability of VPGI. Besides
these four- and five-point scales, other interpretations of
FDG uptake have also been used. Keidar et al. defined an
infectious process if focal increased 18F-FDG uptake in the
region of any of the vascular grafts had a higher intensity
than the surrounding tissues [13]. Spacek et al. interpreted
FDG uptake as intense, inhomogeneous, or no uptake [15].
They considered intense focal FDG uptake as a positive result
for VPGI. However, when inhomogeneous uptake was also
considered as a positive result, then the sensitivity increased
but the specificity decreased. The subgroup of patients with
inhomogeneous FDG uptake represents the big challenge,
because of nondiagnostic results. Spacek et al. suggested that a
mild inhomogeneous FDG uptake might be explained either
by infection of very low grade in which only a weak immune
reaction might be anticipated or in immunocompromised
patients [15]. Hybrid 18F-FDG PET/CT was found as a
promising diagnostic tool in patients with inhomogeneous
FDG uptake with the morphological appearance of the graft
boundary [15]. Because a physiologic uptake is often visible
in or around vascular prostheses, patterns of interpretation
have been discussed. It is believed that a linear, diffuse,
and homogeneous uptake is not likely to represent infection
whereas focal or heterogeneous uptake with projection over
the vessel on CT is highly suggestive of infection [10]. 18F-
FDG PET scans can also be assessed using (semi) qualitative
parameters (maximal standardized uptake value (SUVmax)
and tissue-to-background ratio (TBR)). The TBR ratio can
be calculated by dividing the SUVmax in the graft material
by the mean blood-pool activity [16]. More recently, a semi-
quantitative method has been suggested for the evaluation
of thoracic prosthetic graft infections in which a standard
uptake value-max >8 in the perigraft area was considered
the cut-off value for distinguishing between an infected graft
and a noninfected graft [17]. Until now there are no clear
guidelines for the interpretation of the uptake patterns of
18F-FDG as a signal for VPGI. Apparently the interpretation
of the images by a visual grading scale is predominantly
subjective. Besides visual and semiquantitative analyses, a
quantitative analysis can be performed in which it is possible
to calculate the curve of the arterial FDG concentration
plotted against time (arterial input function). In this way
physiological parameters can be measured in absolute units
(e.g., glucose metabolic rate in mol min−1 g−1 or blood flow
in ml min−1 g−1). Such absolute quantification is usually not
performed in the clinical routine. It requires direct sampling
of arterial blood with serial measurements and dynamic
acquisition. Somenoninvasive alternatives have been studied;
the input function can be retrieved from the PET images
using the aorta or using volumes of interest and partial
volume correction.
6. False-Positive Interpretation of Images and
Graft Physiological Uptake Patterns
Increased 18F-FDG uptake may occur in postsurgical inflam-
matory changes, scar tissue, and native vessels [3, 13, 27].
The chronic aseptic inflammation due to the synthetic graft
material, mediated primarily by macrophages, fibroblasts,
and foreign-body giant cells, constitutes a potential base for
18F-FDG uptake even a long time after surgery, up to 16
years, depending on the used prosthetic material [28–30].
Within the first 6 to 8 weeks after surgery a physiological 18F-
FDG graft uptake can result in a false-positive scan [2, 15, 17]
(Figure 2). These physiological uptake patterns of 18F-FDG
in synthetic vascular graft have been reported in both symp-
tomatic and asymptomatic patients and render a diagnosis of
an early VPGI extremely difficult. In a recent study patients
who underwent an 18F-FDG PET/CT scan for other reasons
than suspected graft infection were analyzed and a 3-grade
arbitrary scale was used, high, low, or no uptake, to indicate
18F-FDG accumulation within the graft. Five circular regions
of interest were drawn at different levels of the descending
and suprarenal abdominal aorta to measure the SUVmean.
The TBR was calculated by dividing the maximum SUV in
the graft material by the mean blood-pool activity. Elevated
18F-FDG was seen in 10 out of 12 patients with synthetic
abdominal aortic grafts after open reconstruction and in
1 out of 4 grafts after endovascular repair. Only 1 patient
eventually developed a VPGI and thus the authors concluded
that the risk of a false-positive diagnosis of VPGI by 18F-FDG
PET/CT shortly after surgery is high [31]. More recently, a
retrospective evaluation of the incidence and patterns of 18F-
FDG uptake in 107 noninfected vascular grafts was published
[32]. A 12-year 18F-FDG PET/CT scan database was searched
for cancer patients with a history of vascular surgery with a
synthetic graft. Again the SUVmean was measured in each
graft and the pattern of uptake for each graft was recorded
as focal, diffuse homogeneous, inhomogeneous, or absent.
Dacron grafts had a significant higher metabolic activity
than Gore-Tex grafts and native vein grafts. Also grafts used
for a central reconstruction had a higher 18F-FDG uptake
compared to grafts anastomosed in the groin or lower limb,
most likely because Dacron is most commonly used during
central reconstruction. Furthermore, the authors found a
diffuse 18F-FDG uptake in 92% of noninfected vascular
prostheses. The intensity of 18F-FDG uptake however was
independent of the period after surgery, ranging from 5
months to 16 years with an average of 10 years [32].
7. 18F-FDG Uptake Patterns in
Diabetes Mellitus Patients
Diabetes mellitus (DM) or elevated serum glucose levels
and its influence on the sensitivity, specificity, and the accu-
racy of 18F-FDG studies are a controversial issue. Glucose
metabolism can be disturbed in DM patients and therefore
result in an increased uptake of 18F-FDG.Anumber of animal
and human studies have shown that plasma glucose competes
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Figure 2: Coronal view of fused 18F-FDG PET/CT image of a culture proven not infected vascular prosthetic graft. In this particular case,
a 45-year-old male patient underwent emergency surgery by placement of a Viabahn in the left common iliac artery because of rupture. He
was admitted to the hospital 6 weeks later with fever and sepsis. 18F-FDG PET/CT scanning showed increased FDG uptake at the level of the
left iliac artery. Ultimately, no bacteria were cultured from the graft under antibiotic therapy.
with 18F-FDG uptake in tumors. It therefore has been pos-
tulated that hyperglycemia may reduce and impair 18F-FDG
uptake in malignant lesions [33–35]. Only a few studies are
available on the role of DM in 18F-FDG uptake in infectious
or inflammatory diseases. A recent study concluded that
the incidence of false-negative scans in patients assessed
for suspicion of an infectious or inflammatory process was
not adversely affected between patients with or without DM
and with high or normal serum glucose levels at the time
of scanning [36]. While not affecting the accuracy when
assessing infection, hyperglycemia during 18F-FDGPET scan
in the oncology group may lead to higher false-negative
rate and should be therefore avoided [36, 37]. For further
interpretation, it is pertinent that FDG-PET reflects glucose
metabolism not only in pathological conditions but also in
various physiological conditions which can cause an increase
in 18F-FDG.These issues require further research in order to
improve the interpretations of 18F-FDG PET in diagnosing
VPGI possible.
8. Uptake Patterns and Causative Organisms
Staphylococcus species are themost common causative organ-
isms of aortic graft infection, mostly due to bacterial con-
tamination at the time of graft placement. Staphylococcus
epidermidis is a slowly growing, slime-producing organism
classically causing a late, indolent VPGI [1, 38, 39]. It is
estimated that Staphylococcus aureus species account for
approximately 25% to 50% of al VPGI [40]. No studies are
available about the differences in uptake patterns of 18F-FDG
in VPGI caused by different species. The 18F-FDG PET char-
acteristics of Staphylococcus aureus osteomyelitis and foreign-
body-associated Staphylococcus epidermidis infections have
been studied in rabbits [41]. Staphylococcus epidermidis was
found to reflect a low virulence of the pathogen and limited
leukocyte infiltration, which was characterized by low 18F-
FDG uptake.
9. Monitoring Response to Treatment with
18F-FDG PET/CT
Recently, the combined guidelines from the European Asso-
ciation of Nuclear Medicine (EANM) and the Society of
Nuclear Medicine and Molecular Imaging (SNMMI) were
published for the use of 18F-FDG PET in inflammation and
infection [42, 43]. Based on cumulated reported accuracies,
more than 85% of these guidelines state that the major
indications for the use of 18F-FDG PET/CT in infection and
inflammation are sarcoidosis, peripheral bone osteomyelitis,
spondylodiscitis, evaluation of fever of unknown origin,
and the primary evaluation of vasculitis [44]. For VPGI,
it remains unclear if 18F-FDG PET/CT offers advantages
over other imaging techniques yet, based on the available
published data [40–44]. However, 18F-FDG PET/CT can not
only be used to diagnose VPGI but it could also be used as
a monitor of treatment response. 18F-FDG PET/CT seems to
be useful for the diagnosis and also for therapy evaluation in
vasculitis, sarcoidosis, and spondylodiscitis [44]. Other well-
described applications, but without sufficient evidence-based
indication, included suspected infection of intravascular
devices, pacemakers, and catheters [45–48]. However to date
there are no studies which show the benefits of 18F-FDG
PET/CT as a monitoring tool for VPGI.
10. Discussion
This review has shown that 18F-FDG PET and 18F-FDG
PET/CTmay play an important role in the detection of VPGI.
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Figure 3: Coronal view of a fused 18F-FDG PET/CT image of a
culture proven infected vascular prosthetic graft. In this particular
case, a 70-year-old male patient underwent an ileofemoral bypass
from the left to right side usingDacron.After 10 years the patientwas
readmitted with an occlusion of the bypass possibly due to a suture
aneurysm. CT scan revealed an occlusion of the bypass with no signs
of infection. 18F-FDG PET/CT scanning clearly showed increased
FDG uptake at the level of the suture aneurysm. Ultimately,
Escherichia coli were cultured from the graft.
However, to date, there is only limited information regarding
the accuracy of 18F-FDG PET/CT imaging in the detection
of these infections. There are no clear guidelines for the
interpretation of 18F-FDG PET images made for suspicion of
VPGI. Because physiologic uptake is often visible in/around
vascular prostheses, the specific patterns of uptake appear to
be crucial. Based on the available literature it is suggested
that a linear, diffuse, and homogeneous uptake should not
be regarded as an infection whereas focal or heterogeneous
uptake with a projection over the vessel on CT is highly
suggestive of infection (Figures 3 and 4). However, low-
grade infection may be presented as mild inhomogeneous of
FDG uptake [15]. In case of inhomogeneous FDG uptake,
we suggest a follow-up policy. 18F-FDG PET scan can not
only be fused with CT scan. Recent studies show the benefits
of fusing PET with MR scan. Possible additional advantages
of PET/MR over PET/CT are the potential for motion cor-
rection, as well as reconstruction driven by anatomic infor-
mation. The combination of PET radiopharmaceuticals and
PET/MR imaging could significantly improve the sensitivity
and specificity of the diagnosis and follow-up treatment of
infectious and inflammatory diseases. It would allow formore
accurate assessment of the extent and exact localization of
inflammatory lesions than PET alone or PET/CT, especially
in soft tissues that are prone to movement artifacts, for
example, in vascular and cardiac infections and inflamma-
tory bowel disease [24]. The development of PET/MR has
triggered a shift in the PET detector technology and image
correction paradigms. Most of the technical challenges have
Figure 4: Axial view of a CT scan and fused 18F FDG PET/CT
image of a culture proven infected vascular prosthetic graft. In this
particular case, a 67-year-old male patient underwent an urgent
endovascular procedure of a contained ruptured abdominal aortic
aneurysm using a Cook Zenith prosthesis. After 7 months the
patient was readmitted with clinical signs of a prosthetic infection.
CT scan was assessed as a possible prosthesis infection. An 18F-FDG
PET/CT scan confirmed the diagnosis by showing an increased FDG
uptake at the level of the endograft. Ultimately, Escherichia coli were
cultured from the graft.
been solved, but clinical studies are required to show the areas
of patient care for which PET/MR has advantages over other
diagnostic methods.
With this current knowledge we recommend to further
develop semiquantitative and quantitative analysis methods
for the assessment of the FDG-PET images. One of the semi-
quantitative values is SUV. It is suggested in the literature
that SUVmax >8 in the perigraft area appears to be the
cut-off value for distinguishing infected grafts from nonin-
fected grafts. However, this was based on a small number
of patients and probably the SUV measurement was not
based on the ENAM and SNMMI guidelines which makes
it difficultly reproducible in other centres. 18F-FDG PET is
generally assessed using visual criteria, looking for a focally
increased uptake that may be compatible with infection. It
is unclear if semiquantitative measurements such as SUV
will contribute to the assessment, partly because of the con-
siderable variability in the methodology used. This recom-
mendation is an attempt to increase uniformity of 18F-FDG
PET investigations in multicentre studies and for routine
clinical applications [43]. It is therefore also essential that
the used equipment is comparable. Besides the development
BioMed Research International 7
of a quantitative analysis and to minimize the false-negative
and false-positive interpretations, an experienced depart-
ment of nuclear medicine is needed to analyze the 18F-FDG
PET/CT scan. Hyperglycemia and DM have been previously
considered as one of the main reasons for false-negative
18F-FDG PET/CT studies. However, based on the available
literature, this appears to be an overestimated problem in
which the false-negative rate in patients assessed for VPGI is
not statistically significantly different between patients with
and without hyperglycemia.
In conclusion,18F-FDG PET and 18F-FDG PET/CT can
play an important role in the detection of VPGI and mon-
itoring response to treatment; however, an accurate uptake
and pattern recognition is warranted. Standardization of
techniques and definitions of the cut-off uptake values and
patterns are needed before recommending the technique as
the new gold standard.
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